In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: A paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 955-968

  Dos Santos, Michel Pinheiro ^a   De Farias, Caroline Brunetto ^a,b,c   Roesler, Rafael ^a,c   Brunetto, Algemir Lunardi ^a,b,c   Abujamra, Ana Lucia ^a,b,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c National Institute for Translational Medicine INCT TM   (Brazil)

Author keywords

Adjuvant therapy; Chemotherapy; Ewing sarcoma; Sodium butyrate; Synergistic effect; Zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID; DOXORUBICIN; ETOPOSIDE; VINCRISTINE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; EWING SARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; SARCOMA CELL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BUTYRIC ACID; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DIPHOSPHONATES; DOXORUBICIN; DRUG SYNERGISM; ETOPOSIDE; HISTAMINE ANTAGONISTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMIDAZOLES; MOLECULAR TARGETED THERAPY; SARCOMA, EWING; TUMOR STEM CELL ASSAY; VINCRISTINE;

EID: 84892378677     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2907     Document Type: Article

References (53)

1. Ricchetti ET, Erol B, Stern J, Russo P, States L and Dormans JP: Lower back pain and mass in a 13-year-old girl. Clin Orthop Relat Res 430: 248-257, 2005.
2. Carvajal R and Meyers P: Ewing's sarcoma and primitive neuroectodermal family of tumors. Hematol Oncol Clin North Am 19: 501-525, 2005.
3. Karosas AO: Ewing's sarcoma. Am J Health Syst Pharm 67: 1599-1605, 2010.
4. Iwamoto Y: Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol 37: 79-89, 2007.
5. Riggi N and Stamenkovic I: The biology of Ewing sarcoma. Cancer Lett 254: 1-10, 2007.
6. Jürgens H and Dirksen U: Ewing sarcoma treatment. Eur J Cancer 47: 366-367, 2011.
7. Bernstein M, Kovar H, Paulussen M, et al: Ewing's sarcoma family of tumors: current management. Oncologist 11: 503-519, 2006.
8. Sonnemann J, Dreyer L, Hartwig M, et al: Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol 133: 847-858, 2007.
9. Johnson IS, Armstrong JG, Gorman M and Burnett JP Jr: The vinca alkaloids: a new class of oncolytic agents. Cancer Res 23: 1390-1427, 1963.
10. Zalupski M and Baker LH: Ifosfamide. J Natl Cancer Inst 80: 556-566, 1988.
11. Hande KR: Etoposide: four decades of development of a topoisomerase II inhibitors. Eur J Cancer 34: 1514-1521, 1998.
12. Schimmel KJ, Richel DJ, Van Den Brink RB and Guchelaar HJ: Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30: 181-191, 2004.
13. Abujamra AL, Dos Santos MP, Roesler R, Schwartsmann G and Brunetto AL: Histone deacetylase inhibitors: a new perspective for the treatment of leukemia. Leuk Res 34: 687-695, 2010.
14. Marks PA: Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 1799: 717-725, 2010.
15. Marks PA: The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19: 1049-1066, 2010.
16. Hoshino I and Matsubara H: Recent advances in histone deacetylase targeted cancer therapy. Surg Today 40: 809-815, 2010.
17. Pili R, Salumbides B, Zhao M, et al: Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 106: 77-84, 2012
18. dos Santos MP, Schwartsmann G, Roesler R, Brunetto AL and Abujamra AL: Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. Leuk Res 33: 218-221, 2009.
19. Clézardin P: Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 48: 71-79, 2011.
20. Stresing V, Daubiné F, Benzaid I, Mönkkönen H and Clézardin P: Bisphosphonates in cancer therapy. Cancer Lett 257: 16-35, 2007.
21. Odri GA, Dumoucel S, Picarda G, et al: Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 70: 7610-7619, 2010.
22. Zhou Z, Guan H, Duan X and Kleinerman ES: Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 104: 1713-1720, 2005.
23. de Oliveira MS, Cechim G, Braganhol E, et al: Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J Neurooncol 93: 191-201, 2009.
24. Flores DG, de Farias CB, Leites J, et al: Gastrin-releasing peptide receptors regulate proliferation of C6 glioma cells through a phosphatidylinositol 3-kinase-dependent mechanism. Curr Neurovasc Res 5: 99-105, 2008.
25. Schmidt AL, de Farias CB, Abujamra AL, et al: BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells. J Mol Neurosci 40: 303-310, 2010.
26. Brunetto de Farias C, Rosemberg DB, Heinen TE, et al: BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer. Oncology 79: 430-439, 2010.
27. Cai Z, Chattopadhyay N, Liu WJ, Chan C, Pignol JP and Reilly RM: Optimized digital counting colonies of clonogenic assays using ImageJ software and customized macros: Comparison with manual counting. Int J Radiat Biol 87: 1135-1146, 2011.
28. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul 22: 27-55, 1984.
29. Chou TC: The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Synergism and Antagonism in Chemotherapy. Chou TC and Rideout DC (eds). Academic Press, San Diego, pp61-102, 1991.
30. Gaspar N, Di Giannatale A, Geoerger B, et al: Bone sarcomas: from biology to targeted therapies. Sarcoma 2012: 301975, 2012. doi: 10.1155/2012/301975.
31. Sakimura R, Tanaka K, Nakatani F, et al: Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 116: 784-792, 2005.
32. Schlottmann S, Erkizan HV, Barber-Rotenberg JS, et al: Acetylation increases EWS-FLI1 DNA binding and transcriptional activity. Front Oncol 2: 1-12, 2012.
33. Li Y, Li X, Fan G, et al: Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Lett 320: 14-22, 2012.
34. Battaglia S, Dumoucel S, Chesneau J, et al: Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient. J Bone Miner Res 26: 2439-2451, 2011.
35. Hirbe AC, Roelofs AJ, Floyd DH, et al: The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 44: 908-916, 2009.
36. Giuliani N, Pedrazzoni M, Passeri G and Girasole G: Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 27: 38-41, 1998.
37. Tenta R, Sourla A, Lembessis P and Koutsilieris M: Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Anticancer Res 26: 283-291, 2006.
38. Muraro M, Mereuta OM, Saglio F, et al: Interactions between osteosarcoma cell lines and dendritic cells immune function: an in vitro study. Cell Immunol 253: 71-80, 2008.
39. Chauvin C, Philippeau J, Hémont C, et al: Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res 68: 9433-9440, 2008.
40. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W and van Valen F: The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs 14: 767-771, 2003.
41. Siddiqui T, Marsh Rde W, Allegra C, et al: Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid. Clin Adv Hematol Oncol 8: 499-504, 2010.
42. Zhao M, Tominaga Y, Ohuchida K, et al: Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Cancer Sci 103: 58-66, 2012.
43. Bayrak OF, Aydemir E, Gulluoglu S, et al: The effects of chemotherapeutic agents on differentiated chordoma cells. J Neurosurg Spine 15: 620-624, 2011.
44. Sonnemann J, Bumbul B and Beck JF: Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther 6: 2976-2984, 2007.
45. Pratap J, Akech J, Wixted JJ, et al: The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 9: 3210-3220, 2010.
46. McGee-Lawrence ME and Westendorf JJ: Histone deacetylases in skeletal development and bone mass maintenance. Gene 474: 1-11, 2011.
47. Winter MC, Holen I and Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34: 453-475, 2008.
48. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G and Budillon A: Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13: 7-26, 2006.
49. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE and Holen I: Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 8: 2821-2832, 2009.
50. Frew AJ, Johnstone RW and Bolden JE: Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280: 125-133, 2009.
51. Blanchard F and Chipoy C: Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10: 197-204, 2005.
52. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006.
53. Kovar H, Alonso J, Aman P, et al: The First European Interdisciplinary Ewing Sarcoma Research Summit. Front Oncol 2: 54, 2012.